Recombinant expression of proteins from secretory cell lines
First Claim
Patent Images
1. A method for the production of human insulin comprising the steps of:
- (a) providing a secretory host cell;
(b) transforming said host cell with an exogenous polynucleotide comprising a gene encoding human insulin, wherein said gene is under the control of a promoter active in eukaryotic cells; and
(c) culturing said secretory host cell under conditions such that said exogenous polynucleotide encoding human insulin expresses human insulin;
wherein said secretory host cell secretes between about 200 ng and about 1000 ng of human insulin/106 cells per hour.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.
45 Citations
59 Claims
-
1. A method for the production of human insulin comprising the steps of:
-
(a) providing a secretory host cell;
(b) transforming said host cell with an exogenous polynucleotide comprising a gene encoding human insulin, wherein said gene is under the control of a promoter active in eukaryotic cells; and
(c) culturing said secretory host cell under conditions such that said exogenous polynucleotide encoding human insulin expresses human insulin;
wherein said secretory host cell secretes between about 200 ng and about 1000 ng of human insulin/106 cells per hour. - View Dependent Claims (2, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)
(d) contacting the secretory host cell with a polynucleotide encoding the Cre protein, wherein said polynucleotide is under the control of a promoter active in eukaryotic cells; and
(e) replicate culturing said cell with and without drug selection.
-
-
35. The method of claim 32, wherein said selectable marker is hygromycin resistance and said drug is hygromycin.
-
36. The method of claim 32, wherein said selectable marker is neomycin and said drug is G418.
-
37. The method of claim 32, wherein said selectable marker is GLUT-2 and said drug is streptozotocin.
-
38. The method of claim 32, wherein the genes for said insulin polypeptide and said selectable marker are part of the same polynucleotide.
-
39. The method of claim 1, wherein said secretory host cell is glucose-responsive.
-
40. The method of claim 2, wherein said blocking of production of said endogenous, secreted polypeptide is effected by interruption of the gene encoding said endogenous, secreted polypeptide.
-
41. The method of claim 40, wherein said interruption is effected by homologous recombination.
-
42. The method of claim 24, wherein said secretory host cell is an insulinoma cell.
-
43. The method of claim 42, wherein said insulinoma cell is a rat insulinoma cell.
-
44. The method of claim 42, wherein said insulinoma cell is a human insulinoma cell.
-
45. The method of claim 31, wherein said exogenous polypeptides is selected from the group consisting of a protein processing enzyme, a receptor and a transcription factor.
-
46. The method of claim 45, wherein said exogenous polypeptide is selected from the group consisting of hexokinase, glucokinase, GLUT-2, GLP-1, IPF1, PC2, PC3, PAM, glucagon-like peptide I receptor, glucose-dependent insulinotropic polypeptide receptor, BIR, SUR, GHRFR and GHRHR.
-
47. The method of claim 38, wherein the genes for said exogenous insulin and said selectable marker are separated on the same polynucleotide by an internal ribosome entry site.
-
48. The method of claim 1, wherein said secretory host cell is not glucose-responsive.
-
49. The method of claim 2, wherein said blocking of production of said endogenous, secreted polypeptide is effected by expression of an RNA antisense to the DNA or mRNA of said endogenous, secreted polypeptide.
-
50. The method of claim 2, wherein said blocking of production of said endogenous, secreted polypeptide is effected by expression of a ribozyme specific for the mRNA of said endogenous, secreted polypeptide.
-
51. The method of claim 40, wherein said interruption is effected by genomic site-directed mutagenesis.
-
52. The method of claim 40, wherein said interruption is effected by random integration.
- 3. A secretory host cell comprising an exogenous polynucleotide comprising a gene encoding human insulin, wherein said cell secretes between about 200 ng and about 1000 ng of insulin/106 cells per hour.
Specification